Literature DB >> 33477142

The Potential of Neurofilament Light as a Biomarker in Alzheimer's Disease.

Yong-Lan Xiong1, Tao Meng2, Jing Luo1, Hua Zhang3.   

Abstract

BACKGROUND: Alzheimer's disease (AD) is the most common neurodegenerative disease characterized by progressive memory loss and cognitive impairment. In 2011, the National Institute on Aging and Alzheimer's Association (NIA-AA) Research Framework has proposed to use biomarkers to diagnose AD in living persons. AD core biomarkers show high diagnostic specificity in distinguishing AD from healthy control subjects, but have little additional value for prognosis or stage of disease.
SUMMARY: With the update of detection methods and techniques, other AD biomarkers have been discovered. Neurofilament light (NFL) is currently recognized as a biomarker of nerve axonal injury and one of the candidate markers in AD neurodegeneration, and the relationship between NFL and AD pathophysiology has attracted widespread attention. More and more studies have shown that NFL plays an important role in predicting the clinical progress and prognosis of AD. Recently, the genome-wide association study also found that multiple single-nucleotide polymorphisms are associated with NFL levels and AD risk. Key Messages: In this review, we discuss the relationship between the genetic characteristics of NFL and AD, the NFL levels in AD, and the relationship between NFL and AD core biomarkers, neuroimaging, and cognitive performance.
© 2021 S. Karger AG, Basel.

Entities:  

Keywords:  Alzheimer’s disease; Biomarkers; Cognitive function; Neurofilament light; Neuroimaging

Year:  2021        PMID: 33477142     DOI: 10.1159/000513008

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  3 in total

1.  A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimer's Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration.

Authors:  Shreyasee Das; Nele Dewit; Dirk Jacobs; Yolande A L Pijnenburg; Sjors G J G In 't Veld; Salomé Coppens; Milena Quaglia; Christophe Hirtz; Charlotte E Teunissen; Eugeen Vanmechelen
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

2.  Salivary Proteomics Identifies Transthyretin as a Biomarker of Early Dementia Conversion.

Authors:  Ece Eldem; Aatmika Barve; Olivier Sallin; Sandrine Foucras; Jean-Marie Annoni; Adrien W Schmid; Lavinia Alberi Auber
Journal:  J Alzheimers Dis Rep       Date:  2022-02-02

Review 3.  Biomarkers of Neurodegenerative Diseases: Biology, Taxonomy, Clinical Relevance, and Current Research Status.

Authors:  Dorota Koníčková; Kateřina Menšíková; Lucie Tučková; Eva Hényková; Miroslav Strnad; David Friedecký; David Stejskal; Radoslav Matěj; Petr Kaňovský
Journal:  Biomedicines       Date:  2022-07-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.